Management Team

当前位置: > Company > Management Team

Management Team

Kevin Pan, Ph.D.

Kevin Pan, Ph.D.

Co-Founder, Chairman, CEO

•  Over 20 years of successful track record in biotech start-up, drug R&D, and business development. Responsible Person for the two projects supported by China’s 12th and 13th “National 5-Year important Innovations” funding programs; Dual-Innovation Talent of Jiangsu Province

•  Founding member of Hutchison Medipharma (Shanghai). Served as Senior Director of Medicinal Chemistry and Executive Director of IP, and contributed to the clinical development of two drugs in the US. Later served as Executive Director of the Business Development department and successfully established strategic partnership with Procter & Gamble, MSD Germany, and Eli Lilly and Company. In 2006, served as core member of the IPO team in successfully raising 40 million pounds in the UK stock market

•  Senior Scientist at Johnson & Johnson and Pfizer, with one responsible drug candidate completed Phase II clinical trial in the US

•  Ph.D. in bio-organic chemistry from Rutgers, the State University of New Jersey. BS in chemistry from Fudan University


John Zhuang, Ph. D.

John Zhuang, Ph. D.

Co-Founder, COO

•  Over 20 years of drug development and management experience at big pharmas. Expertise in regulatory affairs, nonclinical safety assessment, and GMP compliance. Substantial people and project management experience
•  Former Senior Director of Regulatory Affairs at Johnson & Johnson. Led teams in approval or acquisition of multiple drugs and medical devices. Served as Head of Regulatory Affairs and on Management Board of a subsidiary
•  Former Project Leader in Nonclinical Safety Assessment at Eli Lilly and Company. Supported multiple INDs of oncology drugs. Former Senior Scientist at Procter and Gamble Company
•  Invited speaker by China FDA at multiple symposiums. Topics included nonclinical safety assessment of new drugs, US 505(2) and OTC regulations, drug-device combination product regulations
•  PhD in toxicology from Massachusetts Institute of Technology (MIT). MS in physical chemistry and BS in chemistry from Sun Yat-sen University


Gail Brown, M.D., MBA

Gail Brown, M.D., MBA

Acting Chief Medical Officer

•  Over 25 years of clinical research and development experience in designing and conducting phase 1 through phase 3 international clinical trials

•  Most recently served as Chief Medical Officer at ARMO Biosciences, Inc. (NASDAQ: ARMO), which was acquired by Eli Lilly for US$1.6 billion.  At ARMO, built a clinical operations department, advanced their lead product AM0010 from phase 1 to Phase 3 for advanced metastatic pancreatic  cancer, and led two successful End of Phase-2 (Type B) FDA meetings

•  Served as Chief Medical Officer at Telik, Inc. (NASDAQ: TELK) and a senior medical director at AbbVie

•  Consulted for a number of oncology start-up companies and participated in their scientific and clinical advisory boards

•  Began career at Harvard Medical School; served on the faculty of the Department of Medicine, Division of Hematology and oncology at Brigham and Women's Hospital, New England Deaconess Hospital, and Dana Farber Cancer Institute

•  M.D. degree from the University of Rochester School of Medicine, and a M.B.A. degree from St. Mary's College of California Graduate School of Economics and Business Administration 


Yijun Deng, Ph.D.

Yijun Deng, Ph.D.

Vice President of Drug Discovery

•  Over 20 years of experience in the discovery and development of bioactive molecules with pharmaceutical companies in the USA, including Johnson and Johnson, Viropharma Inc, Tetralogic Pharmaceuticals, and Venatorx Pharmaceuticals.

•  Key member of the team discovered birinapant, a first-in-class IAP antagonist for cancer treatment at Tetralogic Pharmaceuticals

•  Extensive experience in Drug Substance and Drug Product Process Development and Manufacturing under GMP. Played a key role in CMC support to the clinical development of birinapant (TL32711), Remetinostat (SHP-141), and a new b-lactamase inhibitor

•  Co-author or co-inventor of more than 30 patents and publications

•  Ph.D. in chemistry from Case Western Reserve University, Cleveland, Ohio; MS and BS in chemistry from Sun Yat-sen University


Ethan Guo, Ph.D.

Ethan Guo, Ph.D.

Vice President of CMC

•  Over 20 years of new drug R&D and management experience. Worked at Merial, Aventis, Sanofi and other pharmaceutical companies;Senior Director of Pharmaceutical Development Services at WuXi AppTec/STA

•  Strong experience in new drug developability assessment, analytical and stability studies, pre-formulation, preclinical and clinical formulation development, especially poorly soluble compounds, CMC, CTD preparation, and outsourcing management

•  Author of four book chapters and expert reviewer for several international pharmaceutical journals

•  Ph.D. in Chemistry from Iowa State University, Postdoc Fellow at Pharmacy School, University of Wisconsin-Madison


David Wilson, Ph.D.

David Wilson, Ph.D.

Senior Vice President, Business Development

•  25 years of success and professional experience in the Pharmaceutical, Diagnostic and Vaccine Industry, where his contributions and professional efforts have directly resulted in increased valuation and subsequent acquisition or IPO resulting in more than $4B USD in increased shareholder value.

•  As VP, Project and Alliance Management for Medarex (acquired by BMS) for Drug Development.  During which, Yervoy and Opdivo where developed as checkpoint inhibitor Immuno-Oncology Drugs and as the Alliance Manager for the Medarex/BMS partnership, the $2.6B USD acquisition of Medarex occurred.

•  Dr. Wilson has extensive domestic and international experience in development and commercialization of high-value Medical Products, owned executive leadership roles in MAST Immunosystems (now Hitachi Medical), Aviron (now Medimmune/Astra Zeneca), Medarex (now Bristol Myers Squibb), Molecular Profiling Institute (now Caris DX), Advanced Biologics

•  Ph.D./MS in Animal Science Biochemistry and Physiology from Cornell University; BA in Biological Sciences from University of California, San Diego


*Based in Scottsdale, Arizona, USA


返回顶部